Summit Securities Group
ANIP icon

Summit Securities Group’s ANI Pharmaceuticals ANIP Stock Holding History

Summit Securities Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.8K Buy
+176
New +$13.6K ﹤0.01% 773
2024
Q1 		– Sell
-2,531
Closed -$140K – 450
2023
Q4 		$140K Buy
+2,531
New +$139K 0.01% 291
2013
Q3 		– Sell
-2
Closed – – 419
2013
Q2 		$0 Buy
+2
New +$14 ﹤0.01% 600

Other funds holding ANIP

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Ranger Investment Management
Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Mizuho Markets Americas
Mizuho Markets Americas New York $6.82B AUM 29.92% 1-Year Est. Return

Summit Securities Group's ANIP Position: Q3 2026 in Review

Summit Securities Group opened a new position in ANI Pharmaceuticals (ANIP) in Q3 2026: 176 shares worth $12.8K. The stake represents ﹤0.01% of the portfolio and ranks #773 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in ANIP as recently as Q4 2023.

Summit Securities Group first reported a position in ANIP in Q2 2013 and has held it in 3 quarters since. The position peaked at $140K in Q4 2023. 147 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • Summit Securities Group held 176 shares of ANI Pharmaceuticals worth $12.8K as of Q3 2026.
  • ANI Pharmaceuticals was a new Summit Securities Group position in Q3 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of Summit Securities Group's portfolio in Q3 2026, its #773 holding.
  • Summit Securities Group first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 3 quarters since.
  • Summit Securities Group's ANI Pharmaceuticals position peaked at $140K in Q4 2023.
  • 147 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.